NovoCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. 

CEO
Frank Leonard
CEOFrank Leonard
Employees
1,605
Employees1,605
Headquarters
St. Helier, Jersey
HeadquartersSt. Helier, Jersey
Founded
2000
Founded2000
Employees
1,605
Employees1,605

NVCR Key Statistics

Market cap
1.58B
Market cap1.58B
Price-Earnings ratio
-12.71
Price-Earnings ratio-12.71
Dividend yield
—
Dividend yield—
Average volume
2.20M
Average volume2.20M
High today
$14.68
High today$14.68
Low today
$13.49
Low today$13.49
Open price
$14.61
Open price$14.61
Volume
1.99M
Volume1.99M
52 Week high
$21.45
52 Week high$21.45
52 Week low
$9.82
52 Week low$9.82

Stock Snapshot

The current NovoCure(NVCR) stock price is $13.53, with a market capitalization of 1.58B. The stock trades at a price-to-earnings (P/E) ratio of -12.71.

As of 2026-11-06, NovoCure(NVCR) stock has fluctuated between $13.49 and $14.68. The current price stands at $13.53, placing the stock +0.3% above today's low and -7.8% off the high.

The NovoCure(NVCR)'s current trading volume is 1.99M, compared to an average daily volume of 2.2M.

In the last year, NovoCure(NVCR) shares hit a 52-week high of $21.45 and a 52-week low of $9.82.

In the last year, NovoCure(NVCR) shares hit a 52-week high of $21.45 and a 52-week low of $9.82.

NVCR News

Simply Wall St 23h
NovoCure Following Raised 2026 Guidance What Does Valuation Say

NovoCure (NVCR) drew fresh attention after raising its 2026 net revenue outlook to US$736 million to US$743 million, paired with third quarter results that show...

NovoCure Following Raised 2026 Guidance What Does Valuation Say
The Motley Fool 4d
NovoCure: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 29, 2026, NovoCure (NVCR +0.30%) announced record quarterly net revenue of $193 million and raised its ful...

NovoCure: 3 Key Takeaways for Long-Term Investors
Simply Wall St 6d
NovoCure Q3 Results Sharpen The Profitability Debate

NovoCure stock barely budged after Q3 2026 earnings, inching up about 0.2% to US$13.14 despite a report that was anything but flat. Traders focused on a bruised...

Analyst ratings

50%

of 6 ratings
Buy
50%
Hold
50%
Sell
0%

More NVCR News

Simply Wall St 7d
Raised Guidance Could Change The Case For NovoCure Stock

NovoCure reported Q3 2026 sales of US$193.4 million compared with US$167.2 million a year earlier, with the quarterly net loss narrowing to US$10.44 million fro...

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.
Upstart
Trade Desk
Shopify
DocuSign
CrowdStrike Holdings
Block

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.